5f96 › Citations

Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody.

Bonsignori M, Zhou T, Sheng Z, Chen L, Gao F, Joyce MG, Ozorowski G, Chuang GY, Schramm CA, Wiehe K, Alam SM, Bradley T, Gladden MA, Hwang KK, Iyengar S, Kumar A, Lu X, Luo K, Mangiapani MC, Parks RJ, Song H, Acharya P, Bailer RT, Cao A, Druz A, Georgiev IS, Kwon YD, Louder MK, Zhang B, Zheng A, Hill BJ, Kong R, Soto C, Mullikin JC, Douek DC, Montefiori DC, Moody MA, Shaw GM, Hahn BH, Kelsoe G, Hraber PT, Korber BT, Boyd SD, Fire AZ, Kepler TB, Shapiro L, Ward AB, Mascola JR, Liao HX, Kwong PD, Haynes BF
Cell 165 449-63 (2016)
Related entries: 5f9o, 5f9w

Cited: 203 times
EuropePMC logo PMID: 26949186

Abstract

Antibodies with ontogenies from VH1-2 or VH1-46-germline genes dominate the broadly neutralizing response against the CD4-binding site (CD4bs) on HIV-1. Here, we define with longitudinal sampling from time-of-infection the development of a VH1-46-derived antibody lineage that matured to neutralize 90% of HIV-1 isolates. Structures of lineage antibodies CH235 (week 41 from time-of-infection, 18% breadth), CH235.9 (week 152, 77%), and CH235.12 (week 323, 90%) demonstrated the maturing epitope to focus on the conformationally invariant portion of the CD4bs. Similarities between CH235 lineage and five unrelated CD4bs lineages in epitope focusing, length-of-time to develop breadth, and extraordinary level of somatic hypermutation suggested commonalities in maturation among all CD4bs antibodies. Fortunately, the required CH235-lineage hypermutation appeared substantially guided by the intrinsic mutability of the VH1-46 gene, which closely resembled VH1-2. We integrated our CH235-lineage findings with a second broadly neutralizing lineage and HIV-1 co-evolution to suggest a vaccination strategy for inducing both lineages.

Reviews - 5f96 mentioned but not cited (1)

  1. Polyvalent vaccine approaches to combat HIV-1 diversity. Korber B, Hraber P, Wagh K, Hahn BH. Immunol. Rev. 275 230-244 (2017)

Articles - 5f96 mentioned but not cited (6)

  1. Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. Bonsignori M, Zhou T, Sheng Z, Chen L, Gao F, Joyce MG, Ozorowski G, Chuang GY, Schramm CA, Wiehe K, Alam SM, Bradley T, Gladden MA, Hwang KK, Iyengar S, Kumar A, Lu X, Luo K, Mangiapani MC, Parks RJ, Song H, Acharya P, Bailer RT, Cao A, Druz A, Georgiev IS, Kwon YD, Louder MK, Zhang B, Zheng A, Hill BJ, Kong R, Soto C, NISC Comparative Sequencing Program, Mullikin JC, Douek DC, Montefiori DC, Moody MA, Shaw GM, Hahn BH, Kelsoe G, Hraber PT, Korber BT, Boyd SD, Fire AZ, Kepler TB, Shapiro L, Ward AB, Mascola JR, Liao HX, Kwong PD, Haynes BF. Cell 165 449-463 (2016)
  2. Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. Roark RS, Li H, Williams WB, Chug H, Mason RD, Gorman J, Wang S, Lee FH, Rando J, Bonsignori M, Hwang KK, Saunders KO, Wiehe K, Moody MA, Hraber PT, Wagh K, Giorgi EE, Russell RM, Bibollet-Ruche F, Liu W, Connell J, Smith AG, DeVoto J, Murphy AI, Smith J, Ding W, Zhao C, Chohan N, Okumura M, Rosario C, Ding Y, Lindemuth E, Bauer AM, Bar KJ, Ambrozak D, Chao CW, Chuang GY, Geng H, Lin BC, Louder MK, Nguyen R, Zhang B, Lewis MG, Raymond DD, Doria-Rose NA, Schramm CA, Douek DC, Roederer M, Kepler TB, Kelsoe G, Mascola JR, Kwong PD, Korber BT, Harrison SC, Haynes BF, Hahn BH, Shaw GM. Science 371 eabd2638 (2021)
  3. Estimation of the breadth of CD4bs targeting HIV antibodies by molecular modeling and machine learning. Conti S, Karplus M. PLoS Comput Biol 15 e1006954 (2019)
  4. research-article Engineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies. Henderson R, Anasti K, Manne K, Stalls V, Saunders C, Bililign Y, Williams A, Bubphamala P, Montani M, Kachhap S, Li J, Jaing C, Newman A, Cain D, Lu X, Venkatayogi S, Berry M, Wagh K, Korber B, Saunders KO, Tian M, Alt F, Wiehe K, Acharya P, Alam SM, Haynes BF. bioRxiv 2023.12.15.571700 (2023)
  5. research-article Microsecond dynamics control the HIV-1 envelope conformation. Bennett AL, Edwards RJ, Kosheleva I, Saunders C, Bililign Y, Williams A, Manosouri K, Saunders KO, Haynes BF, Acharya P, Henderson R. bioRxiv 2023.05.17.541130 (2023)
  6. Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. LaBranche CC, Henderson R, Hsu A, Behrens S, Chen X, Zhou T, Wiehe K, Saunders KO, Alam SM, Bonsignori M, Borgnia MJ, Sattentau QJ, Eaton A, Greene K, Gao H, Liao HX, Williams WB, Peacock J, Tang H, Perez LG, Edwards RJ, Kepler TB, Korber BT, Kwong PD, Mascola JR, Acharya P, Haynes BF, Montefiori DC. PLoS Pathog. 15 e1008026 (2019)


Reviews citing this publication (53)

  1. Germinal Center B Cell Dynamics. Mesin L, Ersching J, Victora GD. Immunity 45 471-482 (2016)
  2. Identification and specificity of broadly neutralizing antibodies against HIV. McCoy LE, Burton DR. Immunol. Rev. 275 11-20 (2017)
  3. Native-like Env trimers as a platform for HIV-1 vaccine design. Sanders RW, Moore JP. Immunol. Rev. 275 161-182 (2017)
  4. Progress toward active or passive HIV-1 vaccination. Escolano A, Dosenovic P, Nussenzweig MC. J. Exp. Med. 214 3-16 (2017)
  5. Use of broadly neutralizing antibodies for HIV-1 prevention. Pegu A, Hessell AJ, Mascola JR, Haigwood NL. Immunol. Rev. 275 296-312 (2017)
  6. Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. Bonsignori M, Liao HX, Gao F, Williams WB, Alam SM, Montefiori DC, Haynes BF. Immunol. Rev. 275 145-160 (2017)
  7. Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem. Havenar-Daughton C, Lee JH, Crotty S. Immunol. Rev. 275 49-61 (2017)
  8. Germinal centers: programmed for affinity maturation and antibody diversification. Bannard O, Cyster JG. Curr. Opin. Immunol. 45 21-30 (2017)
  9. Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. Stephenson KE, Wagh K, Korber B, Barouch DH. Annu Rev Immunol 38 673-703 (2020)
  10. Germline-targeting immunogens. Stamatatos L, Pancera M, McGuire AT. Immunol. Rev. 275 203-216 (2017)
  11. Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies. Borrow P, Moody MA. Immunol. Rev. 275 62-78 (2017)
  12. Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. Fuchs SP, Desrosiers RC. Mol Ther Methods Clin Dev 3 16068 (2016)
  13. Survivors Remorse: antibody-mediated protection against HIV-1. Lewis GK, Pazgier M, DeVico AL. Immunol. Rev. 275 271-284 (2017)
  14. Antigenic landscape of the HIV-1 envelope and new immunological concepts defined by HIV-1 broadly neutralizing antibodies. Wu X, Kong XP. Curr. Opin. Immunol. 42 56-64 (2016)
  15. Coevolution of HIV-1 and broadly neutralizing antibodies. Doria-Rose NA, Landais E. Curr Opin HIV AIDS 14 286-293 (2019)
  16. How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design. Pancera M, Changela A, Kwong PD. Curr Opin HIV AIDS 12 229-240 (2017)
  17. Evolution of B cell analysis and Env trimer redesign. Karlsson Hedestam GB, Guenaga J, Corcoran M, Wyatt RT. Immunol. Rev. 275 183-202 (2017)
  18. Antibodyomics: bioinformatics technologies for understanding B-cell immunity to HIV-1. Kwong PD, Chuang GY, DeKosky BJ, Gindin T, Georgiev IS, Lemmin T, Schramm CA, Sheng Z, Soto C, Yang AS, Mascola JR, Shapiro L. Immunol. Rev. 275 108-128 (2017)
  19. Approaches to the induction of HIV broadly neutralizing antibodies. Moore PL, Williamson C. Curr Opin HIV AIDS 11 569-575 (2016)
  20. HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens. Fischer W, Giorgi EE, Chakraborty S, Nguyen K, Bhattacharya T, Theiler J, Goloboff PA, Yoon H, Abfalterer W, Foley BT, Tegally H, San JE, de Oliveira T, Network for Genomic Surveillance in South Africa (NGS-SA), Gnanakaran S, Korber B. Cell Host Microbe 29 1093-1110 (2021)
  21. Strategies for a multi-stage neutralizing antibody-based HIV vaccine. Andrabi R, Bhiman JN, Burton DR. Curr. Opin. Immunol. 53 143-151 (2018)
  22. What Are the Most Powerful Immunogen Design Vaccine Strategies? A Structural Biologist's Perspective. Kwong PD. Cold Spring Harb Perspect Biol 9 (2017)
  23. Mechanisms of Adaptive Immunity to Porcine Reproductive and Respiratory Syndrome Virus. Rahe MC, Murtaugh MP. Viruses 9 (2017)
  24. Recent progress in broadly neutralizing antibodies to HIV. Sok D, Burton DR. Nat. Immunol. 19 1179-1188 (2018)
  25. Broadly Neutralizing Antibodies against HIV: Back to Blood. Dashti A, DeVico AL, Lewis GK, Sajadi MM. Trends Mol Med 25 228-240 (2019)
  26. Genetic and structural analyses of affinity maturation in the humoral response to HIV-1. Kepler TB, Wiehe K. Immunol. Rev. 275 129-144 (2017)
  27. Glycosylation profiling to evaluate glycoprotein immunogens against HIV-1. Behrens AJ, Struwe WB, Crispin M. Expert Rev Proteomics 14 881-890 (2017)
  28. Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine? Kinchen VJ, Cox AL, Bailey JR. Trends Microbiol. 26 854-864 (2018)
  29. Exploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination Strategies. Kreer C, Gruell H, Mora T, Walczak AM, Klein F. Vaccines (Basel) 8 (2020)
  30. HIV vaccinology: 2021 update. Lee JH, Crotty S. Semin Immunol 51 101470 (2021)
  31. Passive and active antibody studies in primates to inform HIV vaccines. Hessell AJ, Malherbe DC, Haigwood NL. Expert Rev Vaccines 17 127-144 (2018)
  32. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy? Subbaraman H, Schanz M, Trkola A. Retrovirology 15 52 (2018)
  33. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers. Landais E, Moore PL. Retrovirology 15 61 (2018)
  34. Natural infection as a blueprint for rational HIV vaccine design. van Haaren MM, van den Kerkhof TL, van Gils MJ. Hum Vaccin Immunother 13 229-236 (2017)
  35. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Haynes BF, Wiehe K, Borrrow P, Saunders KO, Korber B, Wagh K, McMichael AJ, Kelsoe G, Hahn BH, Alt F, Shaw GM. Nat Rev Immunol (2022)
  36. Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies. Williams WB, Wiehe K, Saunders KO, Haynes BF. J Int AIDS Soc 24 Suppl 7 e25831 (2021)
  37. What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Breaking through Immunity's Glass Ceiling. Kelsoe G, Haynes BF. Cold Spring Harb Perspect Biol 10 (2018)
  38. Beyond Hot Spots: Biases in Antibody Somatic Hypermutation and Implications for Vaccine Design. Schramm CA, Douek DC. Front Immunol 9 1876 (2018)
  39. Harnessing T Follicular Helper Cell Responses for HIV Vaccine Development. Niessl J, Kaufmann DE. Viruses 10 (2018)
  40. Human adaptive immune receptor repertoire analysis-Past, present, and future. Nielsen SCA, Boyd SD. Immunol. Rev. 284 9-23 (2018)
  41. Role of germinal centers for the induction of broadly-reactive memory B cells. Takahashi Y, Kelsoe G. Curr. Opin. Immunol. 45 119-125 (2017)
  42. The role of follicular helper CD4 T cells in the development of HIV-1 specific broadly neutralizing antibody responses. Moysi E, Petrovas C, Koup RA. Retrovirology 15 54 (2018)
  43. An Overview of Human Anti-HIV-1 Neutralizing Antibodies against Diverse Epitopes of HIV-1. Kumar S, Singh S, Luthra K. ACS Omega 8 7252-7261 (2023)
  44. Antibody responses to viral infections: a structural perspective across three different enveloped viruses. Murin CD, Wilson IA, Ward AB. Nat Microbiol 4 734-747 (2019)
  45. HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth. van Schooten J, van Gils MJ. Retrovirology 15 74 (2018)
  46. Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem. Verkoczy L. Adv. Immunol. 134 235-352 (2017)
  47. Immune Correlate-Guided HIV Vaccine Design. Alter G, Barouch D. Cell Host Microbe 24 25-33 (2018)
  48. Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome. Hurwitz JL, Bonsignori M. Viral Immunol. 31 124-132 (2018)
  49. Novel approaches in preclinical HIV vaccine research. Safrit JT, Koff WC. Curr Opin HIV AIDS 11 601-606 (2016)
  50. The Conformational States of the HIV-1 Envelope Glycoproteins. Wang Q, Finzi A, Sodroski J. Trends Microbiol 28 655-667 (2020)
  51. To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1. Griffith SA, McCoy LE. Front Immunol 12 708227 (2021)
  52. Tracing Antibody Repertoire Evolution by Systems Phylogeny. Yermanos AD, Dounas AK, Stadler T, Oxenius A, Reddy ST. Front Immunol 9 2149 (2018)
  53. What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Is Affinity Maturation a Self-Defeating Process for Eliciting Broad Protection? Stamper CT, Wilson PC. Cold Spring Harb Perspect Biol 10 (2018)

Articles citing this publication (143)

  1. Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. Song G, He WT, Callaghan S, Anzanello F, Huang D, Ricketts J, Torres JL, Beutler N, Peng L, Vargas S, Cassell J, Parren M, Yang L, Ignacio C, Smith DM, Voss JE, Nemazee D, Ward AB, Rogers T, Burton DR, Andrabi R. Nat Commun 12 2938 (2021)
  2. Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Li H, Wang S, Kong R, Ding W, Lee FH, Parker Z, Kim E, Learn GH, Hahn P, Policicchio B, Brocca-Cofano E, Deleage C, Hao X, Chuang GY, Gorman J, Gardner M, Lewis MG, Hatziioannou T, Santra S, Apetrei C, Pandrea I, Alam SM, Liao HX, Shen X, Tomaras GD, Farzan M, Chertova E, Keele BF, Estes JD, Lifson JD, Doms RW, Montefiori DC, Haynes BF, Sodroski JG, Kwong PD, Hahn BH, Shaw GM. Proc. Natl. Acad. Sci. U.S.A. 113 E3413-22 (2016)
  3. Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Tian M, Cheng C, Chen X, Duan H, Cheng HL, Dao M, Sheng Z, Kimble M, Wang L, Lin S, Schmidt SD, Du Z, Joyce MG, Chen Y, DeKosky BJ, Chen Y, Normandin E, Cantor E, Chen RE, Doria-Rose NA, Zhang Y, Shi W, Kong WP, Choe M, Henry AR, Laboune F, Georgiev IS, Huang PY, Jain S, McGuire AT, Georgeson E, Menis S, Douek DC, Schief WR, Stamatatos L, Kwong PD, Shapiro L, Haynes BF, Mascola JR, Alt FW. Cell 166 1471-1484.e18 (2016)
  4. Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. Gristick HB, von Boehmer L, West AP, Schamber M, Gazumyan A, Golijanin J, Seaman MS, Fätkenheuer G, Klein F, Nussenzweig MC, Bjorkman PJ. Nat. Struct. Mol. Biol. 23 906-915 (2016)
  5. Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. Bonsignori M, Kreider EF, Fera D, Meyerhoff RR, Bradley T, Wiehe K, Alam SM, Aussedat B, Walkowicz WE, Hwang KK, Saunders KO, Zhang R, Gladden MA, Monroe A, Kumar A, Xia SM, Cooper M, Louder MK, McKee K, Bailer RT, Pier BW, Jette CA, Kelsoe G, Williams WB, Morris L, Kappes J, Wagh K, Kamanga G, Cohen MS, Hraber PT, Montefiori DC, Trama A, Liao HX, Kepler TB, Moody MA, Gao F, Danishefsky SJ, Mascola JR, Shaw GM, Hahn BH, Harrison SC, Korber BT, Haynes BF. Sci Transl Med 9 (2017)
  6. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, Golijanin J, Sievers SA, Sok D, Cai H, Cesar Lorenzi JC, Halper-Stromberg A, Toth I, Piechocka-Trocha A, Gristick HB, van Gils MJ, Sanders RW, Wang LX, Seaman MS, Burton DR, Gazumyan A, Walker BD, West AP, Bjorkman PJ, Nussenzweig MC. Sci Transl Med 9 (2017)
  7. Systems Analysis Reveals High Genetic and Antigen-Driven Predetermination of Antibody Repertoires throughout B Cell Development. Greiff V, Menzel U, Miho E, Weber C, Riedel R, Cook S, Valai A, Lopes T, Radbruch A, Winkler TH, Reddy ST. Cell Rep 19 1467-1478 (2017)
  8. Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. Bailey JR, Flyak AI, Cohen VJ, Li H, Wasilewski LN, Snider AE, Wang S, Learn GH, Kose N, Loerinc L, Lampley R, Cox AL, Pfaff JM, Doranz BJ, Shaw GM, Ray SC, Crowe JE. JCI Insight 2 (2017)
  9. HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage. Landais E, Murrell B, Briney B, Murrell S, Rantalainen K, Berndsen ZT, Ramos A, Wickramasinghe L, Smith ML, Eren K, de Val N, Wu M, Cappelletti A, Umotoy J, Lie Y, Wrin T, Algate P, Chan-Hui PY, Karita E, IAVI Protocol C Investigators, IAVI African HIV Research Network, Ward AB, Wilson IA, Burton DR, Smith D, Pond SLK, Poignard P. Immunity 47 990-1003.e9 (2017)
  10. Tuning environmental timescales to evolve and maintain generalists. Sachdeva V, Husain K, Sheng J, Wang S, Murugan A. Proc Natl Acad Sci U S A 117 12693-12699 (2020)
  11. Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. Saunders KO, Nicely NI, Wiehe K, Bonsignori M, Meyerhoff RR, Parks R, Walkowicz WE, Aussedat B, Wu NR, Cai F, Vohra Y, Park PK, Eaton A, Go EP, Sutherland LL, Scearce RM, Barouch DH, Zhang R, Von Holle T, Overman RG, Anasti K, Sanders RW, Moody MA, Kepler TB, Korber B, Desaire H, Santra S, Letvin NL, Nabel GJ, Montefiori DC, Tomaras GD, Liao HX, Alam SM, Danishefsky SJ, Haynes BF. Cell Rep 18 2175-2188 (2017)
  12. Gene-Specific Substitution Profiles Describe the Types and Frequencies of Amino Acid Changes during Antibody Somatic Hypermutation. Sheng Z, Schramm CA, Kong R, NISC Comparative Sequencing Program, Mullikin JC, Mascola JR, Kwong PD, Shapiro L. Front Immunol 8 537 (2017)
  13. Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8. Soto C, Ofek G, Joyce MG, Zhang B, McKee K, Longo NS, Yang Y, Huang J, Parks R, Eudailey J, Lloyd KE, Alam SM, Haynes BF, NISC Comparative Sequencing Program, Mullikin JC, Connors M, Mascola JR, Shapiro L, Kwong PD. PLoS ONE 11 e0157409 (2016)
  14. Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. Doria-Rose NA, Altae-Tran HR, Roark RS, Schmidt SD, Sutton MS, Louder MK, Chuang GY, Bailer RT, Cortez V, Kong R, McKee K, O'Dell S, Wang F, Abdool Karim SS, Binley JM, Connors M, Haynes BF, Martin MA, Montefiori DC, Morris L, Overbaugh J, Kwong PD, Mascola JR, Georgiev IS. PLoS Pathog. 13 e1006148 (2017)
  15. Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. Saunders KO, Verkoczy LK, Jiang C, Zhang J, Parks R, Chen H, Housman M, Bouton-Verville H, Shen X, Trama AM, Scearce R, Sutherland L, Santra S, Newman A, Eaton A, Xu K, Georgiev IS, Joyce MG, Tomaras GD, Bonsignori M, Reed SG, Salazar A, Mascola JR, Moody MA, Cain DW, Centlivre M, Zurawski S, Zurawski G, Erickson HP, Kwong PD, Alam SM, Levy Y, Montefiori DC, Haynes BF. Cell Rep 21 3681-3690 (2017)
  16. Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. Williams WB, Zhang J, Jiang C, Nicely NI, Fera D, Luo K, Moody MA, Liao HX, Alam SM, Kepler TB, Ramesh A, Wiehe K, Holland JA, Bradley T, Vandergrift N, Saunders KO, Parks R, Foulger A, Xia SM, Bonsignori M, Montefiori DC, Louder M, Eaton A, Santra S, Scearce R, Sutherland L, Newman A, Bouton-Verville H, Bowman C, Bomze H, Gao F, Marshall DJ, Whitesides JF, Nie X, Kelsoe G, Reed SG, Fox CB, Clary K, Koutsoukos M, Franco D, Mascola JR, Harrison SC, Haynes BF, Verkoczy L. Nat Commun 8 1732 (2017)
  17. Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site. Wibmer CK, Gorman J, Anthony CS, Mkhize NN, Druz A, York T, Schmidt SD, Labuschagne P, Louder MK, Bailer RT, Abdool Karim SS, Mascola JR, Williamson C, Moore PL, Kwong PD, Morris L. J. Virol. 90 10220-10235 (2016)
  18. SONAR: A High-Throughput Pipeline for Inferring Antibody Ontogenies from Longitudinal Sequencing of B Cell Transcripts. Schramm CA, Sheng Z, Zhang Z, Mascola JR, Kwong PD, Shapiro L. Front Immunol 7 372 (2016)
  19. Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. Saunders KO, Wiehe K, Tian M, Acharya P, Bradley T, Alam SM, Go EP, Scearce R, Sutherland L, Henderson R, Hsu AL, Borgnia MJ, Chen H, Lu X, Wu NR, Watts B, Jiang C, Easterhoff D, Cheng HL, McGovern K, Waddicor P, Chapdelaine-Williams A, Eaton A, Zhang J, Rountree W, Verkoczy L, Tomai M, Lewis MG, Desaire HR, Edwards RJ, Cain DW, Bonsignori M, Montefiori D, Alt FW, Haynes BF. Science 366 (2019)
  20. Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope. Anthony C, York T, Bekker V, Matten D, Selhorst P, Ferreria RC, Garrett NJ, Karim SSA, Morris L, Wood NT, Moore PL, Williamson C. J. Virol. 91 (2017)
  21. Learning the heterogeneous hypermutation landscape of immunoglobulins from high-throughput repertoire data. Spisak N, Walczak AM, Mora T. Nucleic Acids Res 48 10702-10712 (2020)
  22. A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. Yu F, Song H, Wu Y, Chang SY, Wang L, Li W, Hong B, Xia S, Wang C, Khurana S, Feng Y, Wang Y, Sun Z, He B, Hou D, Manischewitz J, King LR, Song Y, Min JY, Golding H, Ji X, Lu L, Jiang S, Dimitrov DS, Ying T. Cell Host Microbe 22 471-483.e5 (2017)
  23. Co-evolution of HIV Envelope and Apex-Targeting Neutralizing Antibody Lineage Provides Benchmarks for Vaccine Design. Rantalainen K, Berndsen ZT, Murrell S, Cao L, Omorodion O, Torres JL, Wu M, Umotoy J, Copps J, Poignard P, Landais E, Paulson JC, Wilson IA, Ward AB. Cell Rep 23 3249-3261 (2018)
  24. Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. Krebs SJ, Kwon YD, Schramm CA, Law WH, Donofrio G, Zhou KH, Gift S, Dussupt V, Georgiev IS, Schätzle S, McDaniel JR, Lai YT, Sastry M, Zhang B, Jarosinski MC, Ransier A, Chenine AL, Asokan M, Bailer RT, Bose M, Cagigi A, Cale EM, Chuang GY, Darko S, Driscoll JI, Druz A, Gorman J, Laboune F, Louder MK, McKee K, Mendez L, Moody MA, O'Sullivan AM, Owen C, Peng D, Rawi R, Sanders-Buell E, Shen CH, Shiakolas AR, Stephens T, Tsybovsky Y, Tucker C, Verardi R, Wang K, Zhou J, Zhou T, Georgiou G, Alam SM, Haynes BF, Rolland M, Matyas GR, Polonis VR, McDermott AB, Douek DC, Shapiro L, Tovanabutra S, Michael NL, Mascola JR, Robb ML, Kwong PD, Doria-Rose NA. Immunity 50 677-691.e13 (2019)
  25. Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide. Mogus AT, Liu L, Jia M, Ajayi DT, Xu K, Kong R, Huang J, Yu J, Kwong PD, Mascola JR, Ho DD, Tsuji M, Chackerian B. Vaccines (Basel) 8 E765 (2020)
  26. Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth. Smith SA, Burton SL, Kilembe W, Lakhi S, Karita E, Price M, Allen S, Hunter E, Derdeyn CA. PLoS Pathog. 12 e1005989 (2016)
  27. HIV-1 VRC01 Germline-Targeting Immunogens Select Distinct Epitope-Specific B Cell Receptors. Lin YR, Parks KR, Weidle C, Naidu AS, Khechaduri A, Riker AO, Takushi B, Chun JH, Borst AJ, Veesler D, Stuart A, Agrawal P, Gray M, Pancera M, Huang PS, Stamatatos L. Immunity 53 840-851.e6 (2020)
  28. Impact of Pre-exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination. Lindesmith LC, Mallory ML, Jones TA, Richardson C, Goodwin RR, Baehner F, Mendelman PM, Bargatze RF, Baric RS. J. Infect. Dis. 215 984-991 (2017)
  29. Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages. Behrens AJ, Kumar A, Medina-Ramirez M, Cupo A, Marshall K, Cruz Portillo VM, Harvey DJ, Ozorowski G, Zitzmann N, Wilson IA, Ward AB, Struwe WB, Moore JP, Sanders RW, Crispin M. J. Proteome Res. 17 987-999 (2018)
  30. Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. Schommers P, Gruell H, Abernathy ME, Tran MK, Dingens AS, Gristick HB, Barnes CO, Schoofs T, Schlotz M, Vanshylla K, Kreer C, Weiland D, Holtick U, Scheid C, Valter MM, van Gils MJ, Sanders RW, Vehreschild JJ, Cornely OA, Lehmann C, Fätkenheuer G, Seaman MS, Bloom JD, Bjorkman PJ, Klein F. Cell 180 471-489.e22 (2020)
  31. Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies. Hwang JK, Wang C, Du Z, Meyers RM, Kepler TB, Neuberg D, Kwong PD, Mascola JR, Joyce MG, Bonsignori M, Haynes BF, Yeap LS, Alt FW. Proc. Natl. Acad. Sci. U.S.A. 114 8614-8619 (2017)
  32. Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth. Wagh K, Kreider EF, Li Y, Barbian HJ, Learn GH, Giorgi E, Hraber PT, Decker TG, Smith AG, Gondim MV, Gillis L, Wandzilak J, Chuang GY, Rawi R, Cai F, Pellegrino P, Williams I, Overbaugh J, Gao F, Kwong PD, Haynes BF, Shaw GM, Borrow P, Seaman MS, Hahn BH, Korber B. Cell Rep 25 893-908.e7 (2018)
  33. Generation of Long-Lived Bone Marrow Plasma Cells Secreting Antibodies Specific for the HIV-1 gp41 Membrane-Proximal External Region in the Absence of Polyreactivity. Donius LR, Cheng Y, Choi J, Sun ZY, Hanson M, Zhang M, Gierahn TM, Marquez S, Uduman M, Kleinstein SH, Irvine D, Love JC, Reinherz EL, Kim M. J. Virol. 90 8875-8890 (2016)
  34. Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors. Yacoob C, Pancera M, Vigdorovich V, Oliver BG, Glenn JA, Feng J, Sather DN, McGuire AT, Stamatatos L. Cell Rep 17 1560-1570 (2016)
  35. Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes. Ringe RP, Ozorowski G, Yasmeen A, Cupo A, Cruz Portillo VM, Pugach P, Golabek M, Rantalainen K, Holden LG, Cottrell CA, Wilson IA, Sanders RW, Ward AB, Klasse PJ, Moore JP. J. Virol. 91 (2017)
  36. A human inferred germline antibody binds to an immunodominant epitope and neutralizes Zika virus. Magnani DM, Silveira CGT, Rosen BC, Ricciardi MJ, Pedreño-Lopez N, Gutman MJ, Bailey VK, Maxwell HS, Domingues A, Gonzalez-Nieto L, Avelino-Silva VI, Trindade M, Nogueira J, Oliveira CS, Maestri A, Felix AC, Levi JE, Nogueira ML, Martins MA, Martinez-Navio JM, Fuchs SP, Whitehead SS, Burton DR, Desrosiers RC, Kallas EG, Watkins DI. PLoS Negl Trop Dis 11 e0005655 (2017)
  37. Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction. Crooks ET, Osawa K, Tong T, Grimley SL, Dai YD, Whalen RG, Kulp DW, Menis S, Schief WR, Binley JM. Virology 505 193-209 (2017)
  38. HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site. McCurley NP, Domi A, Basu R, Saunders KO, LaBranche CC, Montefiori DC, Haynes BF, Robinson HL. PLoS ONE 12 e0177863 (2017)
  39. Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection. Setliff I, McDonnell WJ, Raju N, Bombardi RG, Murji AA, Scheepers C, Ziki R, Mynhardt C, Shepherd BE, Mamchak AA, Garrett N, Karim SA, Mallal SA, Crowe JE, Morris L, Georgiev IS. Cell Host Microbe 23 845-854.e6 (2018)
  40. Optimal Sequential Immunization Can Focus Antibody Responses against Diversity Loss and Distraction. Wang S. PLoS Comput. Biol. 13 e1005336 (2017)
  41. Superinfection Drives HIV Neutralizing Antibody Responses from Several B Cell Lineages that Contribute to a Polyclonal Repertoire. Williams KL, Wang B, Arenz D, Williams JA, Dingens AS, Cortez V, Simonich CA, Rainwater S, Lehman DA, Lee KK, Overbaugh J. Cell Rep 23 682-691 (2018)
  42. Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development. Wiehe K, Bradley T, Meyerhoff RR, Hart C, Williams WB, Easterhoff D, Faison WJ, Kepler TB, Saunders KO, Alam SM, Bonsignori M, Haynes BF. Cell Host Microbe 23 759-765.e6 (2018)
  43. HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. Meyerhoff RR, Scearce RM, Ogburn DF, Lockwood B, Pickeral J, Kuraoka M, Anasti K, Eudailey J, Eaton A, Cooper M, Wiehe K, Montefiori DC, Tomaras G, Ferrari G, Alam SM, Liao HX, Korber B, Gao F, Haynes BF. AIDS Res. Hum. Retroviruses 33 859-868 (2017)
  44. HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. Bradley T, Yang G, Ilkayeva O, Holl TM, Zhang R, Zhang J, Santra S, Fox CB, Reed SG, Parks R, Bowman CM, Bouton-Verville H, Sutherland LL, Scearce RM, Vandergrift N, Kepler TB, Moody MA, Liao HX, Alam SM, McLendon R, Everitt JI, Newgard CB, Verkoczy L, Kelsoe G, Haynes BF. J. Immunol. 197 4663-4673 (2016)
  45. Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer. He L, Lin X, de Val N, Saye-Francisco KL, Mann CJ, Augst R, Morris CD, Azadnia P, Zhou B, Sok D, Ozorowski G, Ward AB, Burton DR, Zhu J. Front Immunol 8 1025 (2017)
  46. IgA Summons IgG to Take a Hit at HIV-1. Magri G, Cerutti A. Cell Host Microbe 27 854-856 (2020)
  47. Observed Antibody Space: A Resource for Data Mining Next-Generation Sequencing of Antibody Repertoires. Kovaltsuk A, Leem J, Kelm S, Snowden J, Deane CM, Krawczyk K. J. Immunol. 201 2502-2509 (2018)
  48. Role of framework mutations and antibody flexibility in the evolution of broadly neutralizing antibodies. Ovchinnikov V, Louveau JE, Barton JP, Karplus M, Chakraborty AK. Elife 7 (2018)
  49. Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. Song H, Giorgi EE, Ganusov VV, Cai F, Athreya G, Yoon H, Carja O, Hora B, Hraber P, Romero-Severson E, Jiang C, Li X, Wang S, Li H, Salazar-Gonzalez JF, Salazar MG, Goonetilleke N, Keele BF, Montefiori DC, Cohen MS, Shaw GM, Hahn BH, McMichael AJ, Haynes BF, Korber B, Bhattacharya T, Gao F. Nat Commun 9 1928 (2018)
  50. ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection. Mielke D, Bandawe G, Zheng J, Jones J, Abrahams MR, Bekker V, Ochsenbauer C, Garrett N, Abdool Karim S, Moore PL, Morris L, Montefiori D, Anthony C, Ferrari G, Williamson C. PLoS Pathog 17 e1010046 (2021)
  51. Broadly neutralizing antibodies to prevent HIV-1. Cohen MS, Corey L. Science 358 46-47 (2017)
  52. Extensive dissemination and intraclonal maturation of HIV Env vaccine-induced B cell responses. Phad GE, Pushparaj P, Tran K, Dubrovskaya V, Àdori M, Martinez-Murillo P, Vázquez Bernat N, Singh S, Dionne G, O'Dell S, Bhullar K, Narang S, Sorini C, Villablanca EJ, Sundling C, Murrell B, Mascola JR, Shapiro L, Pancera M, Martin M, Corcoran M, Wyatt RT, Karlsson Hedestam GB. J Exp Med 217 (2020)
  53. Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site. Cheng HD, Grimm SK, Gilman MS, Gwom LC, Sok D, Sundling C, Donofrio G, Karlsson Hedestam GB, Bonsignori M, Haynes BF, Lahey TP, Maro I, von Reyn CF, Gorny MK, Zolla-Pazner S, Walker BD, Alter G, Burton DR, Robb ML, Krebs SJ, Seaman MS, Bailey-Kellogg C, Ackerman ME. JCI Insight 3 (2018)
  54. Germinal center entry not selection of B cells is controlled by peptide-MHCII complex density. Yeh CH, Nojima T, Kuraoka M, Kelsoe G. Nat Commun 9 928 (2018)
  55. HIV Immunology Goes Out On a Limb. Doria-Rose NA, Mascola JR. Immunity 44 1088-1090 (2016)
  56. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. LaBranche CC, McGuire AT, Gray MD, Behrens S, Kwong PDK, Chen X, Zhou T, Sattentau QJ, Peacock J, Eaton A, Greene K, Gao H, Tang H, Perez LG, Chen X, Saunders KO, Kwong PD, Mascola JR, Haynes BF, Stamatatos L, Montefiori DC. PLoS Pathog. 14 e1007431 (2018)
  57. Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs. Blasi M, Negri D, Saunders KO, Baker EJ, Stadtler H, LaBranche C, Mildenberg B, Morton G, Ciarla A, Shen X, Wang Y, Rountree W, Balakumaran B, Santra S, Haynes BF, Moody AM, Cara A, Klotman ME. NPJ Vaccines 5 107 (2020)
  58. Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization. Han Q, Bradley T, Williams WB, Cain DW, Montefiori DC, Saunders KO, Parks RJ, Edwards RW, Ferrari G, Mueller O, Shen X, Wiehe KJ, Reed S, Fox CB, Rountree W, Vandergrift NA, Wang Y, Sutherland LL, Santra S, Moody MA, Permar SR, Tomaras GD, Lewis MG, Van Rompay KKA, Haynes BF. Cell Rep 30 1553-1569.e6 (2020)
  59. Regulatory Approved Monoclonal Antibodies Contain Framework Mutations Predicted From Human Antibody Repertoires. Petersen BM, Ulmer SA, Rhodes ER, Gutierrez-Gonzalez MF, Dekosky BJ, Sprenger KG, Whitehead TA. Front Immunol 12 728694 (2021)
  60. Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env. Escolano A, Gristick HB, Gautam R, DeLaitsch AT, Abernathy ME, Yang Z, Wang H, Hoffmann MAG, Nishimura Y, Wang Z, Koranda N, Kakutani LM, Gao H, Gnanapragasam PNP, Raina H, Gazumyan A, Cipolla M, Oliveira TY, Ramos V, Irvine DJ, Silva M, West AP, Keeffe JR, Barnes CO, Seaman MS, Nussenzweig MC, Martin MA, Bjorkman PJ. Sci Transl Med 13 eabk1533 (2021)
  61. Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition. Chuang GY, Zhou J, Acharya P, Rawi R, Shen CH, Sheng Z, Zhang B, Zhou T, Bailer RT, Dandey VP, Doria-Rose NA, Louder MK, McKee K, Mascola JR, Shapiro L, Kwong PD. Structure 27 196-206.e6 (2019)
  62. 5' Rapid Amplification of cDNA Ends and Illumina MiSeq Reveals B Cell Receptor Features in Healthy Adults, Adults With Chronic HIV-1 Infection, Cord Blood, and Humanized Mice. Waltari E, Jia M, Jiang CS, Lu H, Huang J, Fernandez C, Finzi A, Kaufmann DE, Markowitz M, Tsuji M, Wu X. Front Immunol 9 628 (2018)
  63. A Potent anti-Simian Immunodeficiency Virus Neutralizing Antibody Induction Associated with a Germline Immunoglobulin Gene Polymorphism in Rhesus Macaques. Matsuoka S, Kuwata T, Ishii H, Sekizuka T, Kuroda M, Sano M, Okazaki M, Yamamoto H, Shimizu M, Matsushita S, Seki Y, Saito A, Sakawaki H, Hirsch VM, Miura T, Akari H, Matano T. J Virol JVI.02455-20 (2021)
  64. A Zika virus-specific IgM elicited in pregnancy exhibits ultrapotent neutralization. Singh T, Hwang KK, Miller AS, Jones RL, Lopez CA, Dulson SJ, Giuberti C, Gladden MA, Miller I, Webster HS, Eudailey JA, Luo K, Von Holle T, Edwards RJ, Valencia S, Burgomaster KE, Zhang S, Mangold JF, Tu JJ, Dennis M, Alam SM, Premkumar L, Dietze R, Pierson TC, Ooi EE, Lazear HM, Kuhn RJ, Permar SR, Bonsignori M. Cell 185 4826-4840.e17 (2022)
  65. Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth. Roskin KM, Jackson KJL, Lee JY, Hoh RA, Joshi SA, Hwang KK, Bonsignori M, Pedroza-Pacheco I, Liao HX, Moody MA, Fire AZ, Borrow P, Haynes BF, Boyd SD. Nat. Immunol. 21 199-209 (2020)
  66. An entry-competent intermediate state of the HIV-1 envelope glycoproteins. Herschhorn A, Sodroski J. Receptors Clin Investig 4 (2017)
  67. Anti-idiotypic antibodies elicit anti-HIV-1-specific B cell responses. Dosenovic P, Pettersson AK, Wall A, Thientosapol ES, Feng J, Weidle C, Bhullar K, Kara EE, Hartweger H, Pai JA, Gray MD, Parks KR, Taylor JJ, Pancera M, Stamatatos L, Nussenzweig MC, McGuire AT. J. Exp. Med. 216 2316-2330 (2019)
  68. Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor. Alam SM, Cronin K, Parks R, Anasti K, Ding H, Go EP, Desaire H, Eaton A, Montefiori D, Sodroski J, Kappes J, Haynes BF, Saunders KO. J Virol 94 e00958-20 (2020)
  69. Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge. Felber BK, Lu Z, Hu X, Valentin A, Rosati M, Remmel CAL, Weiner JA, Carpenter MC, Faircloth K, Stanfield-Oakley S, Williams WB, Shen X, Tomaras GD, LaBranche CC, Montefiori D, Trinh HV, Rao M, Alam MS, Vandergrift NA, Saunders KO, Wang Y, Rountree W, Das J, Alter G, Reed SG, Aye PP, Schiro F, Pahar B, Dufour JP, Veazey RS, Marx PA, Venzon DJ, Shaw GM, Ferrari G, Ackerman ME, Haynes BF, Pavlakis GN. Cell Rep 31 107624 (2020)
  70. Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity. Prigent J, Jarossay A, Planchais C, Eden C, Dufloo J, Kök A, Lorin V, Vratskikh O, Couderc T, Bruel T, Schwartz O, Seaman MS, Ohlenschläger O, Dimitrov JD, Mouquet H. Cell Rep 23 2568-2581 (2018)
  71. Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2. Gao N, Gai Y, Meng L, Wang C, Wang W, Li X, Gu T, Louder MK, Doria-Rose NA, Wiehe K, Nazzari AF, Olia AS, Gorman J, Rawi R, Wu W, Smith C, Khant H, de Val N, Yu B, Luo J, Niu H, Tsybovsky Y, Liao H, Kepler TB, Kwong PD, Mascola JR, Qin C, Zhou T, Yu X, Gao F. Adv Sci (Weinh) 9 e2200063 (2022)
  72. Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens. Crooks ET, Almanza F, D'Addabbo A, Duggan E, Zhang J, Wagh K, Mou H, Allen JD, Thomas A, Osawa K, Korber BT, Tsybovsky Y, Cale E, Nolan J, Crispin M, Verkoczy LK, Binley JM. PLoS Pathog 17 e1009807 (2021)
  73. Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection. Ndlovu B, Gounder K, Muema D, Raju N, Hermanus T, Mthethwa Q, Robertson K, Walker BD, Georgiev IS, Morris L, Moore PL, Ndung'u T. Virology 546 1-12 (2020)
  74. HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth. Sheward DJ, Marais J, Bekker V, Murrell B, Eren K, Bhiman JN, Nonyane M, Garrett N, Woodman ZL, Abdool Karim Q, Abdool Karim SS, Morris L, Moore PL, Williamson C. Cell Host Microbe 24 593-599.e3 (2018)
  75. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH, Korber B. Cell Host Microbe 25 59-72.e8 (2019)
  76. Improvement of antibody functionality by structure-guided paratope engraftment. Liu Q, Lai YT, Zhang P, Louder MK, Pegu A, Rawi R, Asokan M, Chen X, Shen CH, Chuang GY, Yang ES, Miao H, Wang Y, Fauci AS, Kwong PD, Mascola JR, Lusso P. Nat Commun 10 721 (2019)
  77. In Vitro Evolution of Antibodies Inspired by In Vivo Evolution. Persson H, Kirik U, Thörnqvist L, Greiff L, Levander F, Ohlin M. Front Immunol 9 1391 (2018)
  78. In-Depth Analysis of Human Neonatal and Adult IgM Antibody Repertoires. Hong B, Wu Y, Li W, Wang X, Wen Y, Jiang S, Dimitrov DS, Ying T. Front Immunol 9 128 (2018)
  79. Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. Bonsignori M, Scott E, Wiehe K, Easterhoff D, Alam SM, Hwang KK, Cooper M, Xia SM, Zhang R, Montefiori DC, Henderson R, Nie X, Kelsoe G, Moody MA, Chen X, Joyce MG, Kwong PD, Connors M, Mascola JR, McGuire AT, Stamatatos L, Medina-Ramírez M, Sanders RW, Saunders KO, Kepler TB, Haynes BF. Immunity 49 1162-1174.e8 (2018)
  80. Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations. Swanson O, Rhodes B, Wang A, Xia SM, Parks R, Chen H, Sanzone A, Cooper M, Louder MK, Lin BC, Doria-Rose NA, Bonsignori M, Saunders KO, Wiehe K, Haynes BF, Azoitei ML. Cell Rep 36 109561 (2021)
  81. Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infection. Saunders KO, Edwards RJ, Tilahun K, Manne K, Lu X, Cain DW, Wiehe K, Williams WB, Mansouri K, Hernandez GE, Sutherland L, Scearce R, Parks R, Barr M, DeMarco T, Eater CM, Eaton A, Morton G, Mildenberg B, Wang Y, Rountree RW, Tomai MA, Fox CB, Moody MA, Alam SM, Santra S, Lewis MG, Denny TN, Shaw GM, Montefiori DC, Acharya P, Haynes BF. Sci Transl Med 14 eabo5598 (2022)
  82. The respiratory syncytial virus (RSV) prefusion F-protein functional antibody repertoire in adult healthy donors. Andreano E, Paciello I, Bardelli M, Tavarini S, Sammicheli C, Frigimelica E, Guidotti S, Torricelli G, Biancucci M, D'Oro U, Chandramouli S, Bottomley MJ, Rappuoli R, Finco O, Buricchi F. EMBO Mol Med 13 e14035 (2021)
  83. Virus Evolution and Neutralization Sensitivity in an HIV-1 Subtype B' Infected Plasma Donor with Broadly Neutralizing Activity. Hu Y, Zou S, Wang Z, Liu Y, Ren L, Hao Y, Sun S, Hu X, Ruan Y, Ma L, Shao Y, Hong K. Vaccines (Basel) 9 311 (2021)
  84. eCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly Neutralizing Antibody. Fellinger CH, Gardner MR, Weber JA, Alfant B, Zhou AS, Farzan M. J. Virol. 93 (2019)
  85. A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies. Bibollet-Ruche F, Russell RM, Ding W, Liu W, Li Y, Wagh K, Wrapp D, Habib R, Skelly AN, Roark RS, Sherrill-Mix S, Wang S, Rando J, Lindemuth E, Cruickshank K, Park Y, Baum R, Carey JW, Connell AJ, Li H, Giorgi EE, Song GS, Ding S, Finzi A, Newman A, Hernandez GE, Machiele E, Cain DW, Mansouri K, Lewis MG, Montefiori DC, Wiehe KJ, Alam SM, Teng IT, Kwong PD, Andrabi R, Verkoczy L, Burton DR, Korber BT, Saunders KO, Haynes BF, Edwards RJ, Shaw GM, Hahn BH. mBio 14 e0337022 (2023)
  86. A VH1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite. Kumar S, Ju B, Shapero B, Lin X, Ren L, Zhang L, Li D, Zhou Z, Feng Y, Sou C, Mann CJ, Hao Y, Sarkar A, Hou J, Nunnally C, Hong K, Wang S, Ge X, Su B, Landais E, Sok D, Zwick MB, He L, Zhu J, Wilson IA, Shao Y. Sci Adv 6 (2020)
  87. A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch. Wang Z, Barnes CO, Gautam R, Cetrulo Lorenzi JC, Mayer CT, Oliveira TY, Ramos V, Cipolla M, Gordon KM, Gristick HB, West AP, Nishimura Y, Raina H, Seaman MS, Gazumyan A, Martin M, Bjorkman PJ, Nussenzweig MC, Escolano A. Elife 9 (2020)
  88. A scalable model for simulating multi-round antibody evolution and benchmarking of clonal tree reconstruction methods. Zhang C, Bzikadze AV, Safonova Y, Mirarab S. Front Immunol 13 1014439 (2022)
  89. ARMADiLLO: a web server for analyzing antibody mutation probabilities. Martin Beem JS, Venkatayogi S, Haynes BF, Wiehe K. Nucleic Acids Res 51 W51-W56 (2023)
  90. An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses. Kumar S, Panda H, Makhdoomi MA, Mishra N, Safdari HA, Chawla H, Aggarwal H, Reddy ES, Lodha R, Kumar Kabra S, Chandele A, Dutta S, Luthra K. J. Virol. 93 (2019)
  91. Analysis of B Cell Receptor Repertoires Reveals Key Signatures of the Systemic B Cell Response after SARS-CoV-2 Infection. Zhang Y, Yan Q, Luo K, He P, Hou R, Zhao X, Wang Q, Yi H, Liang H, Deng Y, Hu F, Li F, Liu X, Feng Y, Li P, Qu L, Chen Z, Pan-Hammarström Q, Feng L, Niu X, Chen L. J Virol 96 e0160021 (2022)
  92. Analysis of two cooperating antibodies unveils immune pressure imposed on HIV Env to elicit a V3-glycan supersite broadly neutralizing antibody lineage. Finkelstein MT, Parker Miller E, Erdman MC, Fera D. Front Immunol 13 962939 (2022)
  93. Ancestral sequences from an elite neutralizer proximal to the development of neutralization resistance as a potential source of HIV vaccine immunogens. Mesa KA, Yu B, Wrin T, Petropoulos CJ, Pogson GH, Alexander DL, Perez G, O'Rourke SM, Sinangil F, Robinson J, Conant MA, Berman PW. PLoS ONE 14 e0213409 (2019)
  94. Antibody Repertoire Analysis of Hepatitis C Virus Infections Identifies Immune Signatures Associated With Spontaneous Clearance. Eliyahu S, Sharabi O, Elmedvi S, Timor R, Davidovich A, Vigneault F, Clouser C, Hope R, Nimer A, Braun M, Weiss YY, Polak P, Yaari G, Gal-Tanamy M. Front Immunol 9 3004 (2018)
  95. Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway. Mielke D, Bandawe G, Pollara J, Abrahams MR, Nyanhete T, Moore PL, Thebus R, Yates NL, Kappes JC, Ochsenbauer C, Garrett N, Abdool Karim S, Tomaras GD, Montefiori D, Morris L, Ferrari G, Williamson C. Front Immunol 10 2875 (2019)
  96. Antigen pressure from two founder viruses induces multiple insertions at a single antibody position to generate broadly neutralizing HIV antibodies. Joyce C, Murrell S, Murrell B, Omorodion O, Ver LS, Carrico N, Bastidas R, Nedellec R, Bick M, Woehl J, Zhao F, Burns A, Barman S, Appel M, Ramos A, Wickramasinghe L, Eren K, Vollbrecht T, Smith DM, Kosakovsky Pond SL, McBride R, Worth C, Batista F, Sok D, IAVI Protocol C Investigators & The IAVI African HIV Research Network, Poignard P, Briney B, Wilson IA, Landais E, Burton DR. PLoS Pathog 19 e1011416 (2023)
  97. Assessing immunogenicity barriers of the HIV-1 envelope trimer. Maliqi L, Friedrich N, Glögl M, Schmutz S, Schmidt D, Rusert P, Schanz M, Zaheri M, Pasin C, Niklaus C, Foulkes C, Reinberg T, Dreier B, Abela I, Peterhoff D, Hauser A, Kouyos RD, Günthard HF, van Gils MJ, Sanders RW, Wagner R, Plückthun A, Trkola A. NPJ Vaccines 8 148 (2023)
  98. Characteristics of Envelope Genes in a Chinese Chronically HIV-1 Infected Patient With Broadly Neutralizing Activity. Zhang D, Zou S, Hu Y, Hou J, Hu X, Ren L, Ma L, He X, Shao Y, Hong K. Front Microbiol 10 1096 (2019)
  99. Characteristics of Plasmablast Repertoire in Chronically HIV-Infected Individuals for Immunoglobulin H and L Chain Profiled by Single-Cell Analysis. Liao H, Li S, Yu Y, Yue Y, Su K, Zheng Q, Jiang N, Zhang Z. Front Immunol 10 3163 (2019)
  100. Characterization of human IgM and IgG repertoires in individuals with chronic HIV-1 infection. Tian X, Hong B, Zhu X, Kong D, Wen Y, Wu Y, Ma L, Ying T. Virol Sin 37 370-379 (2022)
  101. Coevolutionary transitions emerging from flexible molecular recognition and eco-evolutionary feedback. Sheng J, Wang S. iScience 24 102861 (2021)
  102. Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage. Sacks D, Wiehe K, Morris L, Moore PL. J Virol 96 e0027022 (2022)
  103. Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting. Cheng C, Xu K, Kong R, Chuang GY, Corrigan AR, Geng H, Hill KR, Jafari AJ, O'Dell S, Ou L, Rawi R, Rowshan AP, Sarfo EK, Sastry M, Saunders KO, Schmidt SD, Wang S, Wu W, Zhang B, Doria-Rose NA, Haynes BF, Scorpio DG, Shapiro L, Mascola JR, Kwong PD. PLoS ONE 14 e0215163 (2019)
  104. Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies. Scheepers C, Kgagudi P, Mzindle N, Gray ES, Moyo-Gwete T, Lambson BE, Oosthuysen B, Mabvakure B, Garrett NJ, Abdool Karim SS, Morris L, Moore PL. PLoS Pathog 18 e1010450 (2022)
  105. Design of human immunodeficiency virus-1 neutralizing peptides targeting CD4-binding site: An integrative computational biologics approach. Vivekanandan S, Vetrivel U, Hanna LE. Front Med (Lausanne) 9 1036874 (2022)
  106. Development of Antibodies with Broad Neutralization Specificities against HIV-1 after Long Term SHIV Infection in Macaques. Gao N, Gai Y, Meng L, Wang C, Zhang X, Wang W, Qin C, Yu X, Gao F. Viruses 12 (2020)
  107. Development of antibody-dependent cell cytotoxicity function in HIV-1 antibodies. Doepker LE, Danon S, Harkins E, Ralph DK, Yaffe Z, Garrett ME, Dhar A, Wagner C, Stumpf MM, Arenz D, Williams JA, Jaoko W, Mandaliya K, Lee KK, Matsen FA, Overbaugh JM. Elife 10 (2021)
  108. Dynamic HIV-1 spike motion creates vulnerability for its membrane-bound tripod to antibody attack. Yang S, Hiotis G, Wang Y, Chen J, Wang JH, Kim M, Reinherz EL, Walz T. Nat Commun 13 6393 (2022)
  109. Exposure of an occluded hemagglutinin epitope drives selection of a class of cross-protective influenza antibodies. Adachi Y, Tonouchi K, Nithichanon A, Kuraoka M, Watanabe A, Shinnakasu R, Asanuma H, Ainai A, Ohmi Y, Yamamoto T, Ishii KJ, Hasegawa H, Takeyama H, Lertmemongkolchai G, Kurosaki T, Ato M, Kelsoe G, Takahashi Y. Nat Commun 10 3883 (2019)
  110. HIV-1 vaccine design through minimizing envelope metastability. He L, Kumar S, Allen JD, Huang D, Lin X, Mann CJ, Saye-Francisco KL, Copps J, Sarkar A, Blizard GS, Ozorowski G, Sok D, Crispin M, Ward AB, Nemazee D, Burton DR, Wilson IA, Zhu J. Sci Adv 4 eaau6769 (2018)
  111. Highly mutated antibodies capable of neutralizing N276 glycan-deficient HIV after a single immunization with an Env trimer. Lee JH, Nakao C, Appel M, Le A, Landais E, Kalyuzhniy O, Hu X, Liguori A, Mullen TM, Groschel B, Abbott RK, Sok D, Schief WR, Crotty S. Cell Rep 38 110485 (2022)
  112. Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies. Tuyishime M, Garrido C, Jha S, Moeser M, Mielke D, LaBranche C, Montefiori D, Haynes BF, Joseph S, Margolis DM, Ferrari G. J Clin Invest 130 5157-5170 (2020)
  113. Increased B Cell Selection Stringency In Germinal Centers Can Explain Improved COVID-19 Vaccine Efficacies With Low Dose Prime or Delayed Boost. Garg AK, Mittal S, Padmanabhan P, Desikan R, Dixit NM. Front Immunol 12 776933 (2021)
  114. Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth. Chukwuma VU, Kose N, Sather DN, Sapparapu G, Falk R, King H, Singh V, Lampley R, Malherbe DC, Ditto NT, Sullivan JT, Barnes T, Doranz BJ, Labranche CC, Montefiori DC, Kalams SA, Haigwood NL, Crowe JE. PLoS ONE 13 e0209437 (2018)
  115. MicroRNA-1297 participates in the repair of intestinal barrier injury in patients with HIV/AIDS via negative regulation of PLCβ1. Bao Y, Guo H, Yang B, Chen F, Zhang Z, Gao J. Mol Cell Biochem 477 2133-2147 (2022)
  116. Moving the needle: Employing deep reinforcement learning to push the boundaries of coarse-grained vaccine models. Faris JG, Orbidan D, Wells C, Petersen BK, Sprenger KG. Front Immunol 13 1029167 (2022)
  117. Neutralization Sensitivity and Evolution of Virus in a Chronic HIV-1 Clade B Infected Patient with Neutralizing Activity against Membrane-Proximal External Region. Tang W, Yuan Z, Wang Z, Ren L, Li D, Wang S, Hao Y, Li J, Shen X, Ruan Y, Shao Y, Liu Y. Pathogens 12 497 (2023)
  118. Neutralization and beyond: Antibodies and HIV-1 acquisition. Thomas AS, Ghulam-Smith M, Sagar M. Curr Top Virol 15 73-86 (2018)
  119. Neutralizing Antibody Induction Associated with a Germline Immunoglobulin Gene Polymorphism in Neutralization-Resistant SIVsmE543-3 Infection. Nomura Y, Matsuoka S, Okazaki M, Kuwata T, Matano T, Ishii H. Viruses 13 1181 (2021)
  120. Optimizing immunization protocols to elicit broadly neutralizing antibodies. Sprenger KG, Louveau JE, Murugan PM, Chakraborty AK. Proc Natl Acad Sci U S A 117 20077-20087 (2020)
  121. Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization. Parks KR, MacCamy AJ, Trichka J, Gray M, Weidle C, Borst AJ, Khechaduri A, Takushi B, Agrawal P, Guenaga J, Wyatt RT, Coler R, Seaman M, LaBranche C, Montefiori DC, Veesler D, Pancera M, McGuire A, Stamatatos L. Cell Rep 29 3060-3072.e7 (2019)
  122. Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers. Nyanhete TE, Edwards RJ, LaBranche CC, Mansouri K, Eaton A, Dennison SM, Saunders KO, Goodman D, Janowska K, Spreng RL, Zhang L, Mudrak SV, Hope TJ, Hora B, Bradley T, Georgiev IS, Montefiori DC, Acharya P, Tomaras GD. Front Immunol 12 670561 (2021)
  123. Rapid and Focused Maturation of a VRC01-Class HIV Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan. Umotoy J, Bagaya BS, Joyce C, Schiffner T, Menis S, Saye-Francisco KL, Biddle T, Mohan S, Vollbrecht T, Kalyuzhniy O, Madzorera S, Kitchin D, Lambson B, Nonyane M, Kilembe W, IAVI Protocol C Investigators, IAVI African HIV Research Network, Poignard P, Schief WR, Burton DR, Murrell B, Moore PL, Briney B, Sok D, Landais E. Immunity 51 141-154.e6 (2019)
  124. Recognition determinants of improved HIV-1 neutralization by a heavy chain matured pediatric antibody. Kumar S, Singh S, Chatterjee A, Bajpai P, Sharma S, Katpara S, Lodha R, Dutta S, Luthra K. iScience 26 107579 (2023)
  125. SIV infection duration largely determines broadening of neutralizing antibody response in macaques. Wu F, Ourmanov I, Kirmaier A, Leviyang S, LaBranche C, Huang J, Whitted S, Matsuda K, Montefiori D, Hirsch VM. J Clin Invest 130 5413-5424 (2020)
  126. SOS and IP Modifications Predominantly Affect the Yield but Not Other Properties of SOSIP.664 HIV-1 Env Glycoprotein Trimers. Ringe RP, Colin P, Torres JL, Yasmeen A, Lee WH, Cupo A, Ward AB, Klasse PJ, Moore JP. J Virol 94 (2019)
  127. Selection of immunoglobulin elbow region mutations impacts interdomain conformational flexibility in HIV-1 broadly neutralizing antibodies. Henderson R, Watts BE, Ergin HN, Anasti K, Parks R, Xia SM, Trama A, Liao HX, Saunders KO, Bonsignori M, Wiehe K, Haynes BF, Alam SM. Nat Commun 10 654 (2019)
  128. Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses. Chuang GY, Shen CH, Cheung CS, Gorman J, Creanga A, Joyce MG, Leung K, Rawi R, Wang L, Yang ES, Yang Y, Zhang B, Zhang Y, Kanekiyo M, Zhou T, DeKosky BJ, Graham BS, Mascola JR, Kwong PD. Front Immunol 12 662909 (2021)
  129. Single-Cell Analysis Suggests that Ongoing Affinity Maturation Drives the Emergence of Pemphigus Vulgaris Autoimmune Disease. Cho A, Caldara AL, Ran NA, Menne Z, Kauffman RC, Affer M, Llovet A, Norwood C, Scanlan A, Mantus G, Bradley B, Zimmer S, Schmidt T, Hertl M, Payne AS, Feldman R, Kowalczyk AP, Wrammert J. Cell Rep 28 909-922.e6 (2019)
  130. Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage. Sacks D, Bhiman JN, Wiehe K, Gorman J, Kwong PD, Morris L, Moore PL. PLoS Pathog. 15 e1008005 (2019)
  131. Structural Basis of Antibody Conformation and Stability Modulation by Framework Somatic Hypermutation. Sheng Z, Bimela JS, Katsamba PS, Patel SD, Guo Y, Zhao H, Guo Y, Kwong PD, Shapiro L. Front Immunol 12 811632 (2021)
  132. Structural Insights from HIV-Antibody Coevolution and Related Immunization Studies. Zhou JO, Ton T, Morriss JW, Nguyen D, Fera D. AIDS Res. Hum. Retroviruses 34 760-768 (2018)
  133. Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. Cai F, Chen WH, Wu W, Jones JA, Choe M, Gohain N, Shen X, LaBranche C, Eaton A, Sutherland L, Lee EM, Hernandez GE, Wu NR, Scearce R, Seaman MS, Moody MA, Santra S, Wiehe K, Tomaras GD, Wagh K, Korber B, Bonsignori M, Montefiori DC, Haynes BF, de Val N, Joyce MG, Saunders KO. PLoS Pathog 17 e1009624 (2021)
  134. Structural basis for breadth development in the HIV-1 V3-glycan targeting DH270 antibody clonal lineage. Henderson R, Zhou Y, Stalls V, Wiehe K, Saunders KO, Wagh K, Anasti K, Barr M, Parks R, Alam SM, Korber B, Haynes BF, Bartesaghi A, Acharya P. Nat Commun 14 2782 (2023)
  135. Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies. Cottrell CA, Manne K, Kong R, Wang S, Zhou T, Chuang GY, Edwards RJ, Henderson R, Janowska K, Kopp M, Lin BC, Louder MK, Olia AS, Rawi R, Shen CH, Taft JD, Torres JL, Wu NR, Zhang B, Doria-Rose NA, Cohen MS, Haynes BF, Shapiro L, Ward AB, Acharya P, Mascola JR, Kwong PD. Cell Rep 37 109922 (2021)
  136. Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s. Tolbert WD, Nguyen DN, Tuyishime M, Crowley AR, Chen Y, Jha S, Goodman D, Bekker V, Mudrak SV, DeVico AL, Lewis GK, Theis JF, Pinter A, Moody MA, Easterhoff D, Wiehe K, Pollara J, Saunders KO, Tomaras GD, Ackerman M, Ferrari G, Pazgier M. Front Immunol 12 787603 (2021)
  137. Congresses The 2017 Keystone Symposium on HIV Vaccines. Cottrell CA, Ward AB. Hum Vaccin Immunother 13 2348-2351 (2017)
  138. Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targeting: the RV217 acute infection cohort study. Marichannegowda MH, Zemil M, Wieczorek L, Sanders-Buell E, Bose M, O'Sullivan AM, King D, Francisco L, Diaz-Mendez F, Setua S, Chomont N, Phanuphak N, Ananworanich J, Hsu D, Vasan S, Michael NL, Eller LA, Tovanabutra S, Tagaya Y, Robb ML, Polonis VR, Song H. EBioMedicine 98 104867 (2023)
  139. Unusual Cysteine Content in V1 Region of gp120 From an Elite Suppressor That Produces Broadly Neutralizing Antibodies. Hutchinson JM, Mesa KA, Alexander DL, Yu B, O'Rourke SM, Limoli KL, Wrin T, Deeks SG, Berman PW. Front Immunol 10 1021 (2019)
  140. Using B cell receptor lineage structures to predict affinity. Ralph DK, Matsen FA. PLoS Comput Biol 16 e1008391 (2020)
  141. Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability. Dubrovskaya V, Tran K, Ozorowski G, Guenaga J, Wilson R, Bale S, Cottrell CA, Turner HL, Seabright G, O'Dell S, Torres JL, Yang L, Feng Y, Leaman DP, Vázquez Bernat N, Liban T, Louder M, McKee K, Bailer RT, Movsesyan A, Doria-Rose NA, Pancera M, Karlsson Hedestam GB, Zwick MB, Crispin M, Mascola JR, Ward AB, Wyatt RT. Immunity 51 915-929.e7 (2019)
  142. cAb-Rep: A Database of Curated Antibody Repertoires for Exploring Antibody Diversity and Predicting Antibody Prevalence. Guo Y, Chen K, Kwong PD, Shapiro L, Sheng Z. Front Immunol 10 2365 (2019)
  143. mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. Mu Z, Wiehe K, Saunders KO, Henderson R, Cain DW, Parks R, Martik D, Mansouri K, Edwards RJ, Newman A, Lu X, Xia SM, Eaton A, Bonsignori M, Montefiori D, Han Q, Venkatayogi S, Evangelous T, Wang Y, Rountree W, Korber B, Wagh K, Tam Y, Barbosa C, Alam SM, Williams WB, Tian M, Alt FW, Pardi N, Weissman D, Haynes BF. Cell Rep 38 110514 (2022)


Quick links